Research
Hormonal
GLP-1 agonists resulted in a percentage of change in body weight of -6.2% at six months.
GLP-1 agonists may be an effective option for weight loss in obese IBD patients.
StrongSupportsmedium confidence
The percentage of change in body weight was -6.2 % (-3.4-[-8.5]) at six months.
Why this rating
Based on the retrospective analysis of a specific patient cohort.
Source
Effectiveness and safety of GLP-1 agonist in obese patients with inflammatory bowel disease
Clara Ramos Belinchón et al. · Revista Española de Enfermedades Digestivas · 2024
DOI 10.17235/reed.2024.10305/2024
cohort · n=16Cited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →